Increased risk of HIV adenovirus type-5 C19 vaccines

  • Updated:1 year ago
  • Reading Time:3Minutes
  • Post Words:773Words
Print Friendly, PDF & Email

Concerns and history of increased-risk of HIV in Adenovirus Ad5 Vaccines such as AstraZeneca and Johnson & Johnson

Johnson & Johnson (Janssen), and the University of Oxford (AstraZeneca) are using genetically engineered common cold viruses to make COVID-19 vaccines. When scientists began creating adenoviral vectors in the 1980s, most worked with a particular kind of adenovirus called Ad5, which ubiquitously infects humans and causes the common cold.

Many scientists hoped to use Ad5 to deliver a human gene that could correct rare genetic mutations—an approach called gene therapy. Those efforts came to a grinding halt in 1999 when a teenage boy with a rare genetic liver disease died after receiving an injection of an Ad5-based gene therapy at the University of Pennsylvania. The large dose of 38 trillion viruses the patient was given sparked massive body-wide inflammation and sent his immune system into overdrive. After that, scientists mostly stopped using adenoviral vectors for gene therapy, in which the dose needs to be high to reach many cells of the body.

In addition, two large clinical trials were halted in 2007 when it became clear that the vaccines didn’t work — and, alarmingly, may have even increased the risk of HIV infections in a subset of people with preexisting immunity to Ad5. In 2012, the Oxford group developed its own chimpanzee-derived vector, ChAdOx1, based on an adenovirus discovered in chimpanzee faeces.

The Oxford team went on to create the spin-off company Vaccitech in 2016 and has developed experimental vaccines for a number of diseases, including AIDS, malaria, tuberculosis, and MERS.

But vaccine developers viewed adenovirus-induced inflammation as an asset.

Use of adenovirus type-5 vectored vaccines: a cautionary tale – The Lancet

“Concerned using Ad5 Vector for COVID-19 Vaccines could increase risk of HIV”

Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary taleLancet. 2020;396(10260):e68-e69. doi:10.1016/S0140-6736(20)32156-5

The concern has played out in the past. Merck & Co. tested an HIV vaccine using an Ad5-based adenovirus vector. Because humans had a pre-existing immunity to this vector, two large clinical trials were halted in 2007 when it became clear that the vaccines didn’t work — and, alarmingly, may have even increased the risk of HIV infections in a subset of people with preexisting immunity to Ad5.

Gray GE, Moodie Z, Metch B, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014; 14: 388-396

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13. PMID: 19012954; PMCID: PMC2721012.

 In 2009, it decided to push forward with a modified version of a planned HIV vaccine trial so long as the participants didn’t have preexisting immunity to Ad5. Results from the 2,500-person study showed that the vaccine was safe, but it still didn’t work.

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine N Engl J Med 2013; 369:2083-2092 DOI: 10.1056/NEJMoa1310566

“Enhanced risk of HIV acquisition using adenovirus serotype 5 (Ad5)-vectored vaccine”

Duerr A Huang Y Buchbinder S et al.
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
J Infect Dis. 2012; 206: 258-266 NCT00095576.

Rigged-Vaccines | Rigged Science

Recommended related reading:

Virologist Luc Montagnier (1932- Feb 2022)
Luc Montagnier who died on the 8th of February 2022, confirmed HIV is in the Spike Protein and has been outspoken along with other virologists about not vaccinating during a pandemic and instead focusing on improving your innate immunity because vaccinating during a pandemic would cause mutant variants, among other warnings such as possible brain and neurological disorders. He is a French Virologist of 78 years and was the winner of the Nobel Prize in Medicine in the year 2008 for discovering the HIV virus and was scheduled to take a part in the Grand Jury Proceeding hearing on February 12, 2022. Just a few weeks ago, he spoke in the Luxembourg parliament against the mandates, calling the injections poison and not vaccines at all.

HIV Spike Protein & HIV Jabs
Scratchpad for HIV narrative shenanigans.

Penny... on Health
Penny... on Health

Truth-seeker, ever-questioning, ever-learning, ever-researching, ever delving further and deeper, ever trying to 'figure it out'. This site is a legacy of sorts, a place to collect thoughts, notes, book summaries, & random points of interests.

DISCLAIMER: The information on this website is not medical science or medical advice. I do not have any medical training aside from my own research and interest in this area. The information I publish is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition. I just report my own results, understanding & research.